Upcoming event

Tags

3D reconstruction, Article of the Month, Artificial intelligence, ASCO GU22, ASCO21, AUA21, augmented reality, biomarkers, Cabozantinib, Carcinoma, CheckMate-214, CheckMate-9ER, Checkpoint Inhibitor, Chronic kidney disease, clampless surgery, Cryosurgery, cystic masses, EAU, EAU21, EAU22, EMUC21, EMUC22, enucleoresection, ERUS 2026, ERUS22, ESMO21, ESMO25, expert interview, Frail patient​, Glomerular filtration rate, Guidelines, histology, imaging, IMDC risk model, International Metastatic Renal Cell Carcinoma Database Consortium, intraoperative cyst rupture, intraoperative ultrasound, Kidney cancer, Laparoscopy, localised renal cell carcinoma, Lymph node metastases, Lymph nodes, Metastasectomy, metastatic disease, metastatic RCC, Mortality, neoadjuvant immunotherapy, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, Overall survival, papillary tumour, Partial nephrectomy, precision therapy, Prognostication, Radical nephrectomy, Radical surgery, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, risk stratification, robot-assisted partial nephrectomy, Robotic, robotic partial nephrectomy, Robotic prostatectomy, Robotic surgery, selective clamping, stereotactic body radiation therapy, Survival outcome, Suture, sutureless partial nephrectomy, Targeted therapies, Treatment response, tumour enucleation, tumour genomics, tumour pseudocapsule rupture, Urological surgery, UROonco2025, UROonco24, UROonco25, UROwebinar, Webinar, zero-ischaemia surgery
Show all

Essential research priorities in renal cancer: a modified delphi consensus statement

European Urology Focus, September 2021

Predicting intra‐operative and postoperative consequential events using machine‐learning techniques in patients undergoing robot‐assisted partial nephrectomy: a Vattikuti Collective Quality Initiative database study

BJU International, April 2021

Three-dimensional Augmented Reality Robot-assisted Partial Nephrectomy in Case of Complex Tumours (PADUA ≥10): A New Intraoperative Tool Overcoming the Ultrasound Guidance

European Urology, August 2020

Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study)

The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium

European Urology Oncology, November 2020

Long-term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E2805 Trial Cohort

European Urology, February 2020

Outcomes of Active Surveillance for Young Patients with Small Renal Masses: Prospective Data from the DISSRM Registry

Journal of Urology, December 2020

Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention

Journal of Clinical Oncology, April 2020

Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy

Cancer, September 2020

Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: The RAPPORT trial

Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial

Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC)

PreviousNext